Gilead Sciences

Vertex Pharmaceuticals

Amgen

Regeneron Pharmaceuticals

IQVIA Hlds

Alnylam Pharmaceuticals

Mettler-Toledo

Biogen

Illumina

Waters

iShares Nasdaq Biotechnology ETF

IBB tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges.

iShares PHLX Semiconductor ETF

NEW YORK--(BUSINESS WIRE)--BlackRock, Inc. (NYSE: BLK) today announced product enhancements to two iShares ETFs as part of an ongoing process to periodically review its product lineup. No action is necessary for investors in the impacted ETFs and no capital gains distributions are currently expected as a result of the transition. iShares Nasdaq Biotechnology ETF (IBB) Effective on or around June 21, 2021, the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) will seek to track the ICE Biotechnolog

BlackRock Announces Product Updates to Two iShares ETFs

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Direxion Daily Healthcare Bull 3x Shares

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Healthcare Investors 

abrdn Life Sciences Investors 

Defiance Nasdaq Junior Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Global X Longevity Thematic ETF

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Pacer BioThreat ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Virtus LifeSci Biotech Clinical Trials ETF

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Diagnosing The Future Of Healthcare

At this point, investors are best off with a pick-and-choose strategy.

Is the Biotech Downturn a Buying Opportunity?

ALPS Medical Breakthroughs ETF

Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) and SPDR S&P Biotech ETF (NYSEArca: XBI) both decreased 5.8% while the iShares Nasdaq Biotechnology ETF (IBB), the largest biotech-related ETF by assets, fell [.

Greater Regulatory Scrutiny Could Weigh on Biotech ETFs

Novavax

Ocugen, Inc.

Vir Biotechnology

Short-term investors may not see the long-term potential.

Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

IBB has appreciated 45% since my last article almost a year ago, but it has failed to beat the market in this period. Because IBB invests in the leading healthcare companies in the world, the pipeline remains very strong and positive returns can be expected in the foreseeable future.

Why I'm Selling iShares Nasdaq Biotechnology ETF Even When The Outlook Is Promising

Global X Robotics & Artificial Intelligence ETF

ProShares Long Online/Short Stores ETF

Global X Cloud Computing ETF

Fidelity MSCI Materials Index ETF

Amplify Online Retail ETF

Johnson & Johnson

First Trust Nasdaq Artificial Intelligence & Robotics ETF

First Trust Cloud Computing ETF

Energy Select Sector SPDR Fund

Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.

5 ETF Investing Areas for March to Boost Returns

Biotech ETFs are climbing Wednesday as the Food and Drug Administration's staff endorsed Johnson & Johnson's coronavirus vaccine for emergency use, a key step in offering a third vaccination to the U.S. marketplace. The staff report released Wednesday is a preliminary step designed to prepare the FDA's Vaccines and Related Biological Products Advisory Committee to make [.

Biotech ETFs Pop Amid Pending J&J Vaccine Approval

Boston Scientific

Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high.

3 Biotech Stocks to Buy As Things Heat Up for the Sector

Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.0% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.5%.

Illumina Earnings, Forward Guidance Strengthen Biotech ETFs

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

How Will Biotech ETFs React to These Q4 Earnings Releases?

First Trust US Equity Opportunities ETF

Invesco QQQ

Invesco S&P 500 Equal Weight Technology ETF

SPDR S&P 500 ETF Trust

Technology Select Sector SPDR Fund

Consumer Discretionary Select Sector SPDR Fund

Niche and sector exchange traded funds would have made you five times your money.

Howard Gold's No-Nonsense Investing: These ‘lucky seven' ETFs left the S&P 500 in the dust in the past decade-plus

ARK Genomic Revolution Multi-Sector ETF

BioNTech SE

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

iShares MSCI USA ESG Optimized ETF

VanEck Video Gaming and eSports ETF

Global X Video Games & Esports ETF 

Xtrackers MSCI USA ESG Leaders Equity ETF

We highlight some ETF areas that held their ground and gained popularity among investors amid the coronavirus crisis.

ETF Areas Thriving During Coronavirus Pandemic

The iShares Nasdaq Biotechnology ETF includes both COVID-19 and other plays. The ETF is up by 26% during the last year and there are questions around further growth.

iShares Nasdaq Biotechnology ETF: Continuous Innovation For Mankind

Moderna

Due to lucrative risk/reward setups and heightened fundamental demand, many active traders will be watching biotech stocks.

Active Traders Look to Biotech for 2021

iShares Russell 2000 ETF

Fidelity NASDAQ Composite Index

First Trust NASDAQ-100 Equal Weighted Index Fund

First Trust NASDAQ Technology Dividend Index Fund

The Nasdaq clocked double-digit gains for two years in a row in 2020. It may log double-digit gains in 2021 all over again if the virus scenario does not improve as fast as expected.

Wil Nasdaq ETFs Win in 2021 After the Best Year Since 2009?

iShares MSCI USA Momentum Factor ETF

Vanguard Information Technology ETF

Here we highlight some ETFs that can help investors make the most of the favorable investing opportunities amid the coronavirus crisis.

Get Your Portfolio Christmas-Ready With These ETFs

Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4% by the afternoon, while the Defiance Nasdaq Junior Biotechnology ETF and the SPDR S&P Biotech ETF both gained 3.5%.

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. became the first country to authorize Pfizer's coronavirus vaccine for emergency use, which is likely to increase pressure on the U.S. Food and Drug [.

As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally

VanEck Vectors Semiconductor ETF

Those of you who are new to the Daily, you probably noticed the references to the Economic Modern Family. Mish developed one index and five sectors as the nucleus of the Family to help you and herself see the real economy as portrayed through a combination of cyclicals and non cyclicals.

Can Tech and Biotech Continue to Break New Highs?

November has been a big month for stock and biotech ETFs, and with the Federal Aviation Administration announcing that it supported the “first mass air shipment” of coronavirus vaccines on Friday, pharmaceutical companies and airlines are now readying networks for wide dissemination, which could be a further boon for biotech ETFs. United Airlines ferried Pfizer's much-touted [.

How Will Vaccine Arrivals Affect Biotech ETFs?

News for iShares Nasdaq Biotechnology ETF ETF (IBB)